News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Morphotek Inc. Announces Initiation of a Sponsored Research Agreement (SRA) with Hokkaido University to Evaluate Amatuximab (MORAb-009) in Advanced Pancreatic Cancer


11/17/2010 10:43:32 AM

EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the company has entered into a sponsored research agreement (SRA) with Hokkaido University to evaluate the anti-tumor effect of amatuximab (MORAb-009) for advanced pancreatic cancer. Funding from this grant will support a pre-clinical study to evaluate the potential of amatuximab alone and in combination with gemcitabine in an adjuvant setting.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES